Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer
of new drug treatments in the fight against cancer and
gastrointestinal disorders and diseases, announced today that Gary S.
Jacob, Ph.D., Chief Executive Officer of Callisto Pharmaceuticals will
present a company update at the BIO InvestorForum 2007 which is being
held on October 9-11, 2007 at the Palace Hotel in San Francisco. Dr.
Jacob's presentation will be on Thursday October 11, 2007, at 3pm in
the Telegraph room at the Palace Hotel.
About Callisto Pharmaceuticals, Inc.
Callisto is a biopharmaceutical company focused on the development
of new drugs to treat various forms of cancer and gastrointestinal
diseases. Callisto's drug candidates include two anti-cancer agents as
well as a drug for gastrointestinal disorders. One of the Company's
lead drug candidates, Atiprimod is presently in a Phase II clinical
trial in advanced carcinoid cancer patients, a neuroendocrine tumor,
and in a Phase I/IIa human clinical trial in relapsed or refractory
multiple myeloma patients. Another anti-cancer drug, L-Annamycin, is
being developed as a treatment for forms of relapsed or refractory
acute leukemia, a currently incurable blood cancer. L-Annamycin is
currently in a Phase I clinical trial in adult relapsed or refractory
acute lymphocytic leukemia, and in a Phase I clinical trial in
children and young adults with refractory or relapsed acute
lymphocytic leukemia or acute myelogenous leukemia. L-Annamycin, a
member of the anthracycline family of proven anti-cancer drugs, has a
novel therapeutic profile, including potential activity against
multi-drug resistant tumors and significantly reduced cardiotoxicity,
or damage to the heart, compared to currently available drug
alternatives. Callisto also has a proprietary drug Guanilib in
preclinical development for gastro-intestinal disorders. Callisto is
also listed on the Frankfurt Stock Exchange under the ticker symbol
CA4. More information is available at http://www.callistopharma.com.
